New FDA rules unleash flood of unvetted blood pressure devices | STAT
Skip to Main Content
My Account
A decade of reporting from the frontiers of health and medicine
Search
Log In
Try STAT+
My Account
News
Latest
STAT10
Business
Biotech
Pharma
Health Tech
Health Insurance
Hospitals
Medical Devices
Washington
Policy
FDA
CDC
NIH
Science
CRISPR
Gene Therapy
Research
Neuroscience
Public Health
H5N1 Bird Flu
Addiction
Covid-19
Abortion
Health Disparities
Infectious Disease
Mental Health
Disease
Cancer
Cardiovascular Disease
Chronic Disease
Diabetes
Alzheimer's
Obesity
Features
The MAHA Diagnosis
Health Care's Colossus
Embedded Bias
Newsletters
Opinion
Columns
Adam Feuerstein
Matthew Herper
Ed Silverman
Reports
E-books
Podcasts
Tools & Trackers
CRISPR Tracker
Breakthrough Device Tracker
Generative AI Tracker
Obesity Drug Tracker
Events
Upcoming Events
Summits
Community
STAT Wunderkinds 2026
Video
Advertise
STAT Brand Studio
What's the word?<br>Test your knowledge with our new weekday mini crossword
Start solving
STAT Plus<br>Health tech
Blood pressure tech floods the market after FDA relaxes wearables oversight
Tech companies including Oura, Samsung seize opportunity, while experts raise concerns
Manage alerts for this article
Email this article
Share this article
The latest model of Oura ring will offer users insights on blood pressure.Emilie Megnien/AP
By Mario Aguilar<br>May 28, 2026
Health Tech Correspondent
Mario Aguilar
[email protected]
Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer wearables. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.
In early January, the Food and Drug Administration delivered on the Trump administration’s deregulatory promises by allowing more wellness products to be marketed without the agency’s authorization. Leaders at smart ring maker Oura swiftly planted the pivot foot.
“As soon as this guidance came out, literally the same day, we started having conversations with our product team around what our roadmap looks like, features that we could bring in and actually ship sooner,” Ricky Bloomfield, the company’s chief medical officer, told STAT less than a week after the FDA announcement. He added: “this guidance helps give us more confidence that we can release features sooner and not have to spend months getting additional clarification from the FDA.”<br>Advertisement
One thing FDA clarified in the updated guidance is that companies can release products that use sensors to “estimate, infer, or output” blood pressure and blood glucose readings without approval, if they are intended for wellness purposes. In a speech at the Consumer Electronics Show the day the guidance was announced, the FDA commissioner at the time, Marty Makary, said his agency would “get out of the way” of products that weren’t making medical or clinical claims. “This reduces the amount of subjectivity by regulators and guesswork by developers,” he said.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
Monthly
$39
Totals $468 per year
$39/month<br>Get Started<br>Totals $468 per year
Starter
$30
for 3 months, then $399/year
$30 for 3 months<br>Get Started<br>Then $399/year
Annual
$399
Save 15%
$399/year<br>Get Started<br>Save 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote<br>Request A Quote<br>Savings start at 25%!
2-10 Users
$300
Annually per user
$300/year<br>Get Started<br>$300 Annually per user
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
Log In
FDA, Policy, STAT+, wearables
Submit a correction requestReprints
Mario Aguilar
Health Tech Correspondent
Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer wearables. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.
Newsletter
Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve.
Please enter a valid email address.<br>Sign Up
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
Recommended
Pharmalot
Pharmalot<br>May 28, 2026
STAT Plus: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more
The Readout
The Readout<br>May 28, 2026
STAT Plus: Ahead of ASCO, all eyes...